Prosight Management, LP Crispr Therapeutics Ag Transaction History

Prosight Management, LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$43.23 - $73.83 $1.47 Million - $2.51 Million	-34,000 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$53.19 - $79.24 $884,868 - $1.32 Million	16,636 Added 95.81%	34,000 $2.13 Million
Q4 2021 Feb 14, 2022	BUY	$70.09 - $111.29 $1.22 Million - $1.93 Million	17,364 New	17,364 $1.32 Million

489

57.9M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.1B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Prosight Management, LP, based on Form 13F filings with the SEC.

Stay updated on Prosight Management, LP with notifications on news.